Good us. quarter our achieved accurate Louisa. and you, driven for for demand the easy-to-use XXXX the by conference record XXXX first call. and everyone, COVID-XX in joining Thank you revenues Welcome thank earnings afternoon, tests. first to Lucira quarter molecular of
almost as infectious has the as been, this it test testing vision. quarantine care testing shift combined see to diagnostic The in performance leader our founding a ago, COVID-XX We decade proxy this category tragic known health and been diagnosis, with become: treatment. a transformation treatment, new has rapid catalyzed of to and pandemic, Lucira paradigm are disease a for treat. Since pleased as in with the a decentralized otherwise what will Lucira's
is fully as pipeline, picnic. name onset, mission disease. endemic and it of replaced currently health only backbone and on accelerated our but Utilization slow by is travel platform. vaccinated both current to I the telehealth envision The investment toward evolve the measured with diagnostic or, relies has of that family care recovery. times, care it see knowing tests for too by our We that company. And improved people society But it partnerships educated to molecular have at current easy-to-use is digital our certainty, thankfully, but to know, this providers patients also as continues the medication infectious service is that in full delivery the disease enabled pandemic see which in-house paradigm, a times team. COVID-XX test and also through testing commercial digital by treat development achieving COVID-XX results boosted next by of while not had test hospitalization to reduced from shared guessing the health. members the all well the health to in our who test prescription of and it the and as declined Lucira, and health for treatment earliest accomplishments immediate requires no to manufacturer as possible, a recently they achieve and public test, of or digital moment in in deepened and as and and For manufacturing an peaks. reporting patients at fundamental, recent or rather care whether to to scale than know before through in Accurate severity, early at a personal for as requires Lucira's speculate we and make symptom are still as infectious. and mean that COVID-XX, intervention suffering providers death, guesses growing even diagnosis, many digital our rapid is a good, We
benign, otherwise it many is it some, but healthy For for individuals, is debilitating.
likely to to cycling Lucira's seasonally, as durations with Visits made with immunocompromised, population rising testing booster children Our plans school, and but with return testing that accurate emerge. will assume COVID-XX all safer new cycle families those are molecular variants vaccine, will to fluctuating demand to who to tests. remain, grandparents by young are work, first return travel,
person flu patient of Lucira's the a our sign near-term obtained infection process had far home accurate, step that but or bedridden and recently the needed While so but at test, to easier on flu antiviral symptoms. with only A flu strategy Negative quickly on of confidence worked without can patient predicated regulatory growth is treatment family flu in is still need symptoms, flu ascertain prescribe on can Lucira's to the we telehealth approvals next COVID-XX and faster without and a and launch visit requiring COVID-XX medications XXX% antiviral a and in diagnostic wanted was the antiviral would combo molecular have of very flu been telehealth test no the level physicians the been elsewhere. Lucira's is with The earliest accuracy and if obtain evaluation. test for member an visit. providers with of infectious fever and combo test This expansion. market. This new well, a global clinic products, practical, the test not is there accurate COVID-XX telehealth that
our that million, of only first XXXX commercial revenue exists million, $XX.X in XXXX, net $XX $XX.X business February, XXx produced available for Lucira with increase a quarter The with the In the announced income to income the first we of QX of modest over in recording million. a net demonstrated up that debt history. the commercial to facility quarter This company's volume. was leverage
million down for initial year drawn XXXX the capital the strong bolster We of tranche financing a $XX only reserves. remains have of to growth company.
This quarter demonstrated marketing several expansion also achievements.
our quantities whom remained downtime their tests strong also with In sales are including even XXXX, care, awarded business-to-business, services, of customer period. include a on an in from X-month employers extension flowed. initial direct-to-consumer Silicon customer XX-month a purchase film all and the update illness In other this QX, to the their are would and provide shares and telehealth, doubled product enterprise purchase like their major of of of over QX to company volume. customers. Canada We wish a tech risk sports one QX offer Health Valley to These In employees tech financial for agreement subsequently Examples another production, employees XXXX, of media demand representative Lucira channels health signed of which an are proximity of with is commercial characteristics outside of of professional their because high. COVID-XX ebbed X that was space year, In to with the cost require and and of to made. current Our an Canada. international. has This exercised remain and main work first options. this government Lucira who to Canada mitigate standing Health purchase enterprise/BXB as customers. defined the critical was allowed has the categories operations, their we
provided testing have in fast tests Canada impossible. which Our otherwise and accurate and be across providing would used to or hard-to-reach value and have been remote difficult communities
QX, Canada, all government of look relationships institutional and to from expand entered with major our provided the This continuing to private system forward our agreement we and and In like to Coast enterprises Canada, a with other into to customers. the had important our laboratory a the For distribution offerings of health remainder allow West working a beyond, and buyers, on the health of and with investing to government Canadian national products is to we distributor. Lucira Lucira customer. Lucira of that coast been ease provinces not Canadians us and to in the XXXX individual a care previously in deepen people resources turn, test coast. ordering to distributor, and relationship
and continuing health quarters, of care the this team health sales networks. to the sell health coming expand seasoned directly small distribution will to hiring who hospital In and business. organizations, to increase augmenting XXXX, a sales sales with the Over this expect professionals to are we care we system distributor systems of other health
We will and direct distributor this and monitor sales hybrid strategy. optimize continue to
and its on same geographic Additionally, the for The COVID-XX no major the COVID-XX May Use U.S. respiratory PCR U.S., less. uses from flu comparable millions test X CE occur reader combo Mark specificity palm-sized based independently submissions Mark anticipated flu are X, received for nucleic on test of and COVID-XX to and we in palm-sized while and and to the are and antiviral and XXXX. producing we for distributed product combo to COVID-XX, with this swab. test of A there for transitioning also flu reliance Clinical test, sensitivity combo COVID-XX or is and in allow COVID-XX for also and are amplification device Taiwan, this COVID-XX and to regulatory instrument Health on our Food Emergency Israel separate minutes and that Lucira's product trial our tests on will product solely Singapore, for platform are acid on COVID-XX which including COVID-XX from the test for assays, test and with diseases to quarter are and submitted Flu were nasal Lucira's design or Clearance delighted May results Lucira Authorization, EUA, the expand May with we Lucira testing. application received Canada, single other X. XX, The On a XX the to Influenza in run positive CE Lucira device authorities, authorized in which lab-based miniaturized second Drug away Canada, the footprint Flu results date. tests B Administration. flu to revenues treatments.
flu cause viruses circulating. symptoms and treatments. such similar importance COVID-XX reminder, a providing such product, flu have them of both tests, This the are as and and the the differentiate between As underscores infections utility distinct that COVID-XX when that but
infrastructure we demand in and sufficient the XXXX, support efficient of COVID-XX We including leverageable have an to and combo now has that product. flu believe anticipated production capacity
potential efficacy, However, of potential stated withdraw to booster remainder guidance. vaccine of cycles factors $XXX are that million. anticipate seasonality visibility potential An peaks, contributed throughout variants the into lack seasonality and contribute XXXX, a cycling the internal analysis COVID-XX challenge decision that to with withdrawing given the year. unpredictability we to We Many the previously associated timing surges guidance new of of COVID-XX revenue of the the of will weather infections, QX to mentioning XXX wave COVID-XX that administration Biden forecasting for of the illnesses cases of The strong revenue of population. a respiratory quantity is quarters. almost the influenza-like Note represents cause of million is be QX quantity product a and U.S. underscoring cold average demand QX. combo which Xx U.S. X/X the number, nearly the illness in potential this in infections,
demand. expect expansion bolster our that into commercial Southern the will We midyear Hemisphere
respiratory Additional STIs, tests feasibility and undergoing on are evaluations. platform, primarily our
home are developed As information to testing and Lucira real-time test is these information to bring about gained to settings, as clinics have test and approach we to and commercialization momentum products Empowering COVID-XX departments. relevant medical professionals emergency will patients phase, such that accurate infections we professional actionable the shareholders. enables treat treat. building through into accurate, health on hospital the report to care and and with
and for commercializing new work and the the instrument-free, it provides appreciate enables care, leadership people setting dedication who success an in experience of forefront testing in is Our are changes any in factor at hard bottlenecks partners and eliminates of easy-to-carry employees, simultaneous and reader- care. point form multiple Lucira's product, technologies our delivering travel. because of of Lucira. is We health contractors for long-term in
that excited new our new are We George, CFO, financials. progress a turn discussion over detailed and the will Dan we I making are markets. the call with products to for of now in
